Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026




Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment

TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI®), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. The analysis was presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.

In real‑world clinical practice, patients with chronic diseases who stay on their treatments longer tend to experience better clinical outcomes and higher satisfaction.1,2 Ninety-four percent of patients who completed 18 months of lecanemab treatment in the Phase III Clarity AD chose to continue maintenance treatment by enrolling in the subsequent open-label, long-term extension (OLE) study. In the OLE of Clarity AD study, patients continue to benefit from four years of lecanemab treatment compared with the natural course of Alzheimer’s disease (Alzheimer’s Disease Neuroimaging Initiative: ADNI*).

Long-Term Persistence and Patient Characteristics for Lecanemab in Real-World Use in the United States (Presentation: March 20, 17:05 CET)
This analysis is the first time real-world lecanemab data on treatment persistence beyond 18 months has been reported.

This study was a retrospective observational analysis using the PurpleLab® CLEAR Claims database, a comprehensive dataset based on medical insurance claims across the United States and was conducted to evaluate the long‑term treatment persistence of lecanemab in real‑world clinical practice.

■ Patient background and dosing
The analysis population consisted of 10,763 individuals who met the requirement for continuous healthcare encounters, out of the 13,388 individuals recorded in the database who received at least one intravenous treatment with lecanemab between January 6, 2023 and November 30, 2025. At baseline, the mean age was 73.8 years and 56.5% were female. The most common comorbidities were dyslipidemia (42.2%) and hypertension (36.9%). The mean follow-up duration was 350.9 days. The average number of administrations was 1.7 per month, and the mean dosing interval was 16.4 days (median 14 days), which was generally consistent with the recommended every two weeks dosing.

■ Long-Term persistence results
The time-dependent proportion of patients who remained on lecanemab treatment was evaluated, using the Kaplan–Meier method in a subgroup of 371 patients who initiated treatment in 2023 and had 20 months of continuous follow-up, thereby enabling assessment of long-term treatment persistence beyond 18 months. As a result, 78.4% of individuals continued lecanemab treatment at 18 months, 71.7% at 20 months, and 67.3% at 24 months. Of the 78.4% of patients who remained on lecanemab at 18 months, the majority of them continued treatment during the maintenance period beyond 18 months, confirming a high rate of treatment persistence with lecanemab in real-world clinical practice. The patient characteristics and dosing patterns observed in this claims-based analysis were generally similar to those reported in the Clarity AD. Furthermore, the relatively high treatment adherence observed among individuals suggests that potential delays due to MRI monitoring requirements, adverse events, and other factors did not substantially affect lecanemab dosing.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

* ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of AD and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.

MEDIA CONTACTS  
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Europe, Ltd.
(Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 7739-600-678
EMEA-comms@eisai.net

Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945
Libby_Holman@Eisai.com

Biogen Inc.
Madeleine Shin
+1-781-464-3260
public.affairs@biogen.com

INVESTOR CONTACTS  
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Tim Power
+ 1-781-464-2442
IR@biogen.com


Notes to Editors

1. About lecanemab (generic name, brand name: LEQEMBI)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.

In the global Phase 3 placebo-controlled, double-blind, parallel-group, randomized Clarity AD core study, the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale. To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.3,4

Over three years of treatment, including both the core study and the OLE, data showed lecanemab demonstrated a reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER** cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four years mark.

Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

** BioFINDER subjects are similar to Study 301 and ADNI subjects, except all BioFINDER subjects are in the MCI stage and no mild AD subjects are included, and their baseline CDR-SB is lower. BioFINDER is a large-scale, long-term prospective study led by Lund University in Sweden, aiming to establish early. diagnosis and elucidate pathophysiology of neurodegenerative diseases. In addition to AD, the study also focuses on conditions including Parkinson’s Disease. Individuals participating in the study undergo regular clinical assessments, cognitive function tests, brain imaging (MRI, Aβ PET, Tau PET), and collection of biomarkers from blood and cerebrospinal fluid (CSF).

2. About Protofibrils
Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.3 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.4

3. About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

4. About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.

5. About Eisai Co., Ltd.
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

6. About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.


Biogen Safe Harbor

This news release contains forward-looking statements, including about the potential clinical effects of lecanemab (marketed as LEQEMBI); the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI); the potential to expand options and reduce healthcare resources by treating Alzheimer’s disease at home; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

  1. Guerci B et al. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Therapy, 2019; 10(2), 437-449.
  2. Menditto E et al. Persistence as a robust indicator of medication adherence-related quality and performance. International journal of environmental research and public health, 2021; 18(9), 4872.
  3. Cohen S., et al. J Prev Alzheimers Dis.2022;9(3):507-522.
  4. Morris JC. Neurology. 1993;43(11):2412-4.
  5. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12:3451. doi:10.1038/s41467-021-23507-z
  6. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting




Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris’ Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD).

Electronic Poster Details:

   
Title  Results from an Open-Label Phase 2 Trial of ATI-2138, an Investigational Oral Covalent Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK) And Janus Kinase 3 (JAK3), in Patients with Moderate-To-Severe Atopic Dermatitis
Authors Ajay Aggarwal1, Aparna Kaul1, Loreen Stillwell1, Nancy McGraw1, Robert Mahe1, Rakesh Basavalingappa1, Emma Huff1, David R. Anderson1, Emma Guttman2, Joseph Monahan1, Neal Walker1
  Affiliations: 1Aclaris Therapeutics Inc.; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
   

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
        
Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors

Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors




Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors

–Veteran global investment leader joins neurotechnology company advancing AI-enabled brain health platforms–

BALTIMORE, March 20, 2026 (GLOBE NEWSWIRE) — Longeviti Neuro Solutions, a neurotechnology company developing advanced implantable and AI-enabled solutions for neurological health including the ClearFit AI™, the first Acoustic Brain Interface (ABI)™, today announced the appointment of Robert W. Sharps, Chief Executive Officer and President of T. Rowe Price Group, Inc. (NASDAQ: TROW), to its Board of Directors.

Sharps brings three decades of leadership experience in global asset management, capital markets, corporate governance, and strategic growth. As CEO and the Chairman of the Board of T. Rowe Price, he oversees one of the world’s leading investment firms, managing more than $1.5 trillion in assets for individuals, institutions, and retirement investors worldwide.

Robert Sharps

“Rob’s leadership and perspective at the intersection of finance, governance, and long-term value creation will be invaluable as Longeviti continues to grow,” said Jesse Christopher, Founder of Longeviti Neuro Solutions. “His experience guiding a global investment organization will help strengthen our strategic planning, governance, and partnerships as we scale the company. His perspective will support the acceleration of our clinical and commercial initiatives, the continued expansion of our ClearFit AI™ platform, and the advancement of our long-term therapeutic roadmap including work in blood-brain barrier disruption.”

Longeviti Neuro Solutions is a neuro platform company developing technologies designed to advance the understanding and treatment of neurological conditions while supporting long-term brain health and human performance. The company is known for its FDA-cleared products, including ClearFit AI™, the first Acoustic Brain Interface (ABI)™. Its ClearFit AI™ platform integrates advanced imaging, artificial intelligence, and precision engineering to enhance planning, placement, and analysis for neurotechnology and implantable solutions.

“I am pleased to join the board of Longeviti Neuro Solutions during a period of significant advancement in neuroscience and medical technology,” said Sharps. “The company’s work combining artificial intelligence, data insights, and innovative neurotechnology represents an important opportunity to improve the way neurological conditions are studied and treated. I look forward to supporting the leadership team as they continue building and scaling the company’s platform.”

Sharps joined T. Rowe Price in 1997 and has held a variety of leadership and investment roles within the organization. He became Chief Executive Officer and President in 2022 and previously served as Chief Investment Officer and Head of Investments, overseeing the firm’s global investment platform.

His appointment reflects Longeviti’s continued effort to expand its leadership team with experienced advisors from technology, medicine, and global business as the company advances its next generation of proprietary neuro-implant and AI-driven technology solutions aimed at improving neurological health, longevity, and cognitive outcomes.

About Longeviti Neuro Solutions (https://longeviti.com)
Longeviti Neuro Solutions is a neurotechnology company focused on developing advanced implantable, AI-enabled, and non-invasive solutions designed to enhance neurological health, longevity, and human potential while expanding the possibilities of brain-centered medicine. By combining engineering innovation, neuroscience, and artificial intelligence, Longeviti is redefining the future of brain-centered healthcare and therapeutics, and working to advance new approaches to understanding, treating, and optimizing brain function. Longeviti is known for its FDA-cleared products, including ClearFit AI™, the first Acoustic Brain Interface (ABI)™.

The Baltimore-based company has full in-house manufacturing, packaging, design, and sterilization capabilities, with multiple FDA clearances, successful FDA audits, and ISO 13485 certification. Longeviti holds more than 50 patents worldwide, with products approved for use in over 120 hospitals globally. To date, Longeviti neurosurgical implants have been used in more than 4,000 patients.

Contact: Nicole Halsey/Natalie Van Buskirk
  Polished Nichols PR & Marketing
  nicole@polishednichols.com
  natalie@polishednichols.com
  410.952.2122/443.956.4765
   

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bdef4106-2781-4f4a-9a2f-f52bccb9e971

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting




Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

– New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted


– Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo

WILMINGTON, Del.–(BUSINESS WIRE)–$INCY #AAD2026–Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver.

“At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.”

Details on key data presentations at AAD include:

Late-Breaking Oral Presentations

Hidradenitis Suppurativa

Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies

(Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00 p.m. MT)

ePoster Exhibits

Atopic Dermatitis

Ruxolitinib Cream Improves Patient-Reported Outcomes in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

​(Abstract #: 75312)

Ruxolitinib Cream Is Efficacious in Adults With Moderate Atopic Dermatitis Regardless of Baseline Disease Severity and Previous Medication History

​(Abstract #: 70667)

Hidradenitis Suppurativa

Povorcitinib for Moderate-to-Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results in Anti-TNF-Experienced Patients

(Abstract #: 75195)

Physician Perspectives on Diagnosis and Treatment of Hidradenitis Suppurativa: Results From the Global HERALD (Hidradenitis Suppurativa Experiences in the Real World) Survey

​(Abstract #: 75265)

Disease Burden and Treatment History of Hidradenitis Suppurativa: Patient Perspectives From the Global HERALD (Hidradenitis Suppurativa Experiences in the Real World) Survey

​(Abstract #: 75268)

Vitiligo

Association Between Repigmentation and Quality of Life Among Patients With Vitiligo Treated With Ruxolitinib Cream in the TRuE-V Studies

​(Abstract #: 75247)

Real-World Factors Influencing Vitiligo Care: Insights From a Patient Survey Assessing the Use of Ruxolitinib Cream

​(Abstract #: 75258)

More information regarding the 2026 AAD Annual Meeting can be found at: https://www.aad.org/member/meetings-education/am26/education.

About Povorcitinib

Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as a Phase 2 trial for asthma.

About Opzelura® (ruxolitinib) Cream

Opzelura® (ruxolitinib) cream, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. FDA for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.

In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Incyte has worldwide rights for the development and commercialization of Opzelura.

Opzelura is a registered trademark of Incyte.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Incyte Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline and the potential for povorcitinib to provide a safe and effective treatment option for HS and further strengthen the significant growth potential of Incyte’s Inflammation and Autoimmunity franchise, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte’s products; the acceptance of Incyte’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions




LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

MADISON, N.J.–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, Colorado), highlighting new real-world and clinical data across its medical dermatology portfolio and pipeline for inflammatory skin diseases.


Key data to be presented by LEO Pharma at AAD 2026 include:

  • ADBRY® (tralokinumab) 12‑month real‑world data from the TRACE study evaluating the safety and effectiveness of ADBRY among patients with atopic dermatitis (AD), including analyses in patients with hand and foot involvement and patients with skin of color.1-3
  • ANZUPGO® (delgocitinib) data evaluating outcomes with ANZUPGO cream 20 mg/g in adults with moderate-to-severe chronic hand eczema (CHE), including results across patients with and without prior systemic therapy exposure, further characterizing treatment response in this difficult-to-treat population.4
  • SPEVIGO® (spesolimab) long-term data from the EFFISAYIL program evaluating intravenous and subcutaneous SPEVIGO for treatment of GPP flares and characterizing baseline non‑flaring disease phenotype.5-7

“We’re proud to present LEO Pharma’s largest body of research to date at the AAD Annual Meeting, highlighting new real-world and clinical insights across Atopic Dermatitis, Generalized Pustular Psoriasis and Chronic Hand Eczema,” said Sophie Lamle, EVP, Development at LEO Pharma. “Together, these findings reflect continued advancements in the understanding and management of chronic dermatologic diseases and underscore our ambition to help address critical treatment gaps for patients.”

The company’s full roster of presentations at the 2026 AAD Annual Meeting is listed below.1-17

AAD 2026 Scientific Abstracts Presented by LEO Pharma

Author

Format & Timing

Tralokinumab – Atopic Dermatitis

 

 

Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate to severe Atopic Dermatitis: Final data from the prospective, noninterventional, international TRACE study

Armstrong AW, Rubin C, Jarell A, et al.

 

Online ePoster with an Oral Poster Presentation

March 27, 2026

2:05 – 2:10 PM MT

Real-world effectiveness of 12 months tralokinumab in 495 adult Atopic Dermatitis patients with hand and feet involvement: Final data from the prospective, non-interventional, international TRACE study

Armstrong AW, Rodriguez A, Jarell A, et al.

 

Online ePoster

with an Oral Poster Presentation

 

March 28, 2026

3:45 – 3:50 PM MT

Minimal disease activity with 12 months of tralokinumab treatment in adults with Atopic Dermatitis: Real-world data from the prospective, non-interventional, international, TRACE study

Pink A, Pezzolo E, Jarell A, et al.

 

Online ePoster

Spesolimab – Generalized Pustular Psoriasis

 

 

Intravenous spesolimab for (re)treatment of Generalized Pustular Psoriasis flares in patients receiving subcutaneous spesolimab: Results from the 5‑year, open‑label EFFISAYIL® ON extension study

Gordon K, Navarini A, Choon SE, et al.

 

Online ePoster

Long‑term (≥3‑year) efficacy of subcutaneous spesolimab treatment for prevention of flares in patients with Generalized Pustular Psoriasis: Results from the EFFISAYIL® program

Gudjonsson J, Navarini A, Langley R, et al.

 

Online ePoster

Characterization of Generalized Pustular Psoriasis (GPP) severity via individual GPP Physician Global Assessment (GPPGA) components during a non-flaring period: Baseline data from EFFISAYIL® 2

Lebwohl MG, Morita A, Mostaghimi A, et al.

 

Online ePoster

Delgocitinib – Chronic Hand Eczema

 

 

Delgocitinib cream 20 mg/g for moderate to severe Chronic Hand Eczema: outcomes over 16 weeks by prior systemic therapy exposure

Bissonnette R, Schliemann S, Worm M, et al.

Online ePoster with an Oral Presentation

 

March 28, 2026

8:50 – 8:55 AM MT

Patient-perceived factors associated with Chronic Hand Eczema–Results from the CHECK study in the United States

Simpson E, Balu S, Bin Sawad A, et al.

Online ePoster with an Oral Presentation

 

March 28, 2026

2:45 – 2:50 PM MT

Sustained Health-Related Quality of Life improvements with Delgocitinib 20 mg/g Cream in Chronic Hand Eczema – Results from the Phase 3 Open-Label Extension DELTA 3 Trial

Armstrong AW, Stein Gold L, Bauer A, et al.

Online ePoster

Health-related quality of life in people with Chronic Hand Eczema – Results from the CHECK study in the United States

Chovatiya R, Balu S, Bin Sawad A, et al.

 

Online ePoster

 

The DELTA TEEN Phase 3 trial: systemic exposure and safety profile of delgocitinib cream in adolescents with moderate to severe Chronic Hand Eczema

Molin S, Baselga E, Navarro‑Triviño FJ, et al.

 

 

Online ePoster

Pyoderma Gangrenosum

 

 

Prevalence of comorbidities in patients with Pyoderma Gangrenosum (PG) in the U.S.

 

Mostaghimi A, Dini V, Bohn RL, et al.

 

Online ePoster with​

an Oral Presentation​

 

March 29, 2026

1:00 – 1:05 PM MT

Mortality and adverse outcomes in patients with Pyoderma Gangrenosum (PG) in the U.S.

 

Mostaghimi A, Hall C, Bohn RL, et al.

 

Online ePoster with​

an Oral Presentation​

 

March 29, 2026

2:20 – 2:25 PM MT

Patient perspectives on the signs, symptoms and impacts of Pyoderma Gangrenosum (PG): A qualitative study

 

Mostaghimi A, Jha RK, Nokela M, et al.

 

Online ePoster

Psoriasis

 

 

Cost Effectiveness Analysis of Biological Drugs Targeting IL-17 Pathway in Plaque Psoriasis from the Perspective of the Brazilian Private Healthcare System

Muzy G, Magalhaes AMF, Colli LG, et al.

 

Online ePoster with

an Oral Presentation

March 27, 2026

10:05 – 10:10 AM MT

Systemic Immune-Inflammation Index (SII) and systemic inflammation response index (SIRI) trend in Psoriatic patients treated with brodalumab: A real-life pilot study

Mastorino L, Dapavo P, Cangialosi L, et al.

 

Online ePoster with

an Oral Presentation

Epithelial-Derived IL-17C and IL-17E as Psoriatic Inflammation Amplifiers and Targets​

 

Muzy G, Magalhaes AMF, Vargas ALBSJ, et al.

 

Online ePoster

About Atopic Dermatitis

Atopic Dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.18 AD is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.19 Type 2 cytokines, including IL-13, play an important role in the key aspects of AD pathophysiology.18-19 Excessive IL-22 production is also known to contribute to the pathogenesis of AD.20

About Generalized Pustular Psoriasis

Generalized Pustular Psoriasis (GPP) is a chronic, heterogeneous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment.21,22 GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems.23,24 GPP symptoms appear unpredictably and present on a continuum, which greatly impacts a patient’s quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities and finances.24,25

About Chronic Hand Eczema

Chronic Hand Eczema (CHE) is defined as Hand Eczema (HE) that lasts for more than three months or relapses twice or more within a year.26 HE is one of the most common skin disorders of the hands, and in a substantial number of patients it can develop into a chronic condition.27 CHE affects approximately one in ten adults in the U.S.28 It is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on the hands and wrists.26 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.29

CHE has been shown to cause psychological and functional burdens that impact patient quality of life.30,31 Individuals living with CHE experience substantial impairment in daily activities, with an average activity impairment of more than 40%.32 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.33

About ADBRY® (tralokinumab)/ADTRALZA® (tralokinumab)

ADBRY® (tralokinumab), which is marketed outside of the U.S. under the tradename ADTRALZA® (tralokinumab), is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.34,35 Tralokinumab specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).36

Tralokinumab is approved for the treatment of moderate-to-severe AD in adult and adolescent patients 12 years and older in the European Union, Canada, Great Britain, the United Arab Emirates, South Korea, the U.S., and Saudi Arabia. Tralokinumab is approved for use in adults with moderate- to-severe AD in Switzerland and Japan.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR ADBRY® (TRALOKINUMAB)

What is ADBRY?

  • ADBRY® (tralokinumab) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ADBRY can be used with or without topical corticosteroids.
  • It is not known if ADBRY is safe and effective in children under 12 years of age.

Do not use ADBRY if you are allergic to tralokinumab or to any of its ingredients.

What should I discuss with my healthcare provider before starting ADBRY?

Tell your healthcare provider about all your medical conditions, including if you:

  • have eye problems.
  • have a parasitic (helminth) infection.
  • are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with ADBRY.
  • are pregnant or plan to become pregnant. It is not known whether ADBRY will harm your unborn baby. There is a pregnancy exposure registry for women who use ADBRY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.
  • are breastfeeding or plan to breastfeed. It is not known whether ADBRY passes into your breast milk and if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use ADBRY?

  • See the detailed “Instructions for Use” that comes with ADBRY for information on how to prepare and inject ADBRY and how to properly store and throw away (dispose of) used ADBRY prefilled syringes and autoinjectors.
  • Use ADBRY exactly as prescribed by your healthcare provider.
  • Your healthcare provider will tell you how much ADBRY to inject and when to inject it.
  • ADBRY comes as a single-dose prefilled syringe with needle guard or as an autoinjector.
  • ADBRY is given as an injection under the skin (subcutaneous injection).
  • If your healthcare provider decides that you or a caregiver can give the injections of ADBRY, you or your caregiver should receive training on the right way to prepare and inject ADBRY. Do not try to inject ADBRY until you have been shown the right way by your healthcare provider. In children 12 years of age and older, it is recommended that ADBRY be given by or under supervision of an adult.
  • If you miss a dose, inject the missed dose as soon as possible, then continue with your next dose at your regular scheduled time.
  • If you inject too much ADBRY than prescribed, call your healthcare provider or call Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
  • Your healthcare provider may prescribe other medicines to use with ADBRY. Use the other prescribed medicines exactly as your healthcare provider tells you to.

What are the possible side effects of ADBRY?

ADBRY can cause serious side effects including:

  • Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

    • breathing problems
    • itching
    • skin rash
    • swelling of the face, mouth, and tongue
    • fainting, dizziness, feeling lightheaded (low blood pressure)
    • hives
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.

The most common side effects of ADBRY include:

  • upper respiratory tract infections
  • Eye and eyelid inflammation, including redness, swelling, and itching
  • Injection site reactions
  • High count of a certain white blood cell (eosinophilia)

These are not all the possible side effects of ADBRY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please click here for full U.S. Prescribing Information, including Patient Information and Instructions for Use.

About SPEVIGO® (spesolimab)

SPEVIGO® (spesolimab) is a humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP.37 It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP.38-40

INDICATION AND IMPORTANT SAFETY INFORMATION FOR SPEVIGO® (SPESOLIMAB)

INDICATION

SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age or older and weighing at least 40 kg.

CONTRAINDICATIONS

SPEVIGO is contraindicated in patients with severe or life-threatening hypersensitivity to spesolimab or to any of the excipients in SPEVIGO. Reported hypersensitivity reactions have included drug reaction with eosinophilia and systemic symptoms (DRESS).

WARNINGS AND PRECAUTIONS

Infections: SPEVIGO may increase the risk of infections. In patients with a chronic infection or a history of recurrent infection, consider the potential risks and expected clinical benefits of treatment prior to prescribing SPEVIGO. Treatment with SPEVIGO is not recommended in patients with any clinically important active infection until the infection resolves or is adequately treated. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur during or after treatment with SPEVIGO. If a patient develops a clinically important active infection, discontinue SPEVIGO therapy until the infection resolves or is adequately treated.

Risk of Tuberculosis: Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SPEVIGO. Avoid use of SPEVIGO in patients with active TB infection. Consider initiating anti-TB therapy prior to initiating SPEVIGO in patients with latent TB or a history of TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SPEVIGO treatment.

Hypersensitivity and Infusion-Related Reactions:

  • SPEVIGO-associated hypersensitivity reactions may include immediate reactions, such as anaphylaxis, and delayed reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS).
  • Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in clinical trials with spesolimab in subjects with GPP.
  • If a patient develops signs of anaphylaxis or other serious hypersensitivity, discontinue SPEVIGO immediately and initiate appropriate treatment.
  • If a patient develops mild or moderate hypersensitivity during an intravenous infusion or other infusion-related reactions, stop SPEVIGO infusion and consider appropriate medical therapy (e.g., systemic antihistamines and/or corticosteroids). Upon resolution of the reaction, the infusion may be restarted at a slower infusion rate with gradual increase to complete the infusion.

Vaccinations: Prior to initiating SPEVIGO for treatment of GPP, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients during and for at least 16 weeks after treatment with SPEVIGO. No specific studies have been conducted in SPEVIGO-treated patients who have recently received live viral or live bacterial vaccines.

ADVERSE REACTIONS

Intravenous SPEVIGO for Treatment of GPP Flare (Study Effisayil-1): Most common adverse reactions reported in ≥5% of patients treated with SPEVIGO in the clinical trial were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection (UTI).

Specific Adverse Reactions

  • Infections: The most frequent adverse reactions that occurred in subjects treated with intravenous SPEVIGO were infections. During the 1-week placebo-controlled period in Study Effisayil-1, infections were reported in 14% of subjects treated with SPEVIGO compared with 6% of subjects treated with placebo. Serious infection (UTI) was reported in 1 subject (3%) in the SPEVIGO group and no subjects in the placebo group. Infections observed through Week 1 in Study Effisayil-1 in subjects treated with SPEVIGO were mild (29%) to moderate (71%).
  • Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Two cases of DRESS were reported in Study Effisayil-1 in subjects with GPP who were treated with intravenous SPEVIGO. RegiSCAR DRESS validation scoring (with the following categories: “no,” “possible,” “probable,” or “definite” DRESS) was applied to the reported cases. Reported cases were assessed as “no DRESS” and “possible DRESS.”

Subcutaneous SPEVIGO for Treatment of GPP When Not Experiencing a Flare (Study Effisayil-2): Regarding the exposure-adjusted incidence rates for subjects on randomized treatment prior to receiving rescue treatment for flare or completing trial without a flare, the rate per 100-patient years for injection site reaction (including erythema, pain, swelling, induration, urticaria, and warmth at the injection site) was 31.6 for the subcutaneous SPEVIGO cohort (600 mg loading dose followed by 300 mg every 4 weeks) vs 12.7 for the placebo cohort. The rate per 100-patient years for UTI was 18 for SPEVIGO vs 0 for placebo. The rate per 100-patient years for pruritus was 8.8 for SPEVIGO vs 0 for placebo. The rate per 100-patient years for arthralgia was 13.3 for SPEVIGO vs 6 for the placebo cohort. There were 3 subjects who discontinued subcutaneous SPEVIGO due to treatment-emergent adverse events of psoriasis compared to no subjects in the placebo cohort who discontinued placebo for any treatment-emergent adverse event.

Safety in Study Effisayil-2 After Flare: In Effisayil-2, subjects who experienced a GPP flare and received at least one dose of an open-label single intravenous 900 mg dose of SPEVIGO were treated with open-label subcutaneous SPEVIGO 300 mg. These subjects (n=19) received subcutaneous dosing at every 12 weeks, which could have been increased to every 4 weeks based on GPPPGA total score or pustulation subscore increased by ≥1 from any previous open-label maintenance visit. The reported safety profile of open-label subcutaneous SPEVIGO use after treatment of GPP flare with open-label intravenous SPEVIGO use was consistent with the safety profiles of use of SPEVIGO from Trial Effisayil-1 and randomized controlled data from Trial Effisayil-2.

Clinical Development of Spesolimab

  • Guillain-Barre Syndrome (GBS): Among approximately 835 subjects exposed to spesolimab during clinical development, GBS was reported in 3 subjects who received various doses of spesolimab via various methods of administration in clinical trials for unapproved indications.

SPECIFIC POPULATIONS

Pediatric Use: The safety and effectiveness of SPEVIGO for the treatment of GPP have been established in pediatric patients 12 years of age and older and weighing at least 40 kg. Use of SPEVIGO for this indication is supported by data from a randomized, placebo-controlled study, which included 6 pediatric subjects 14 to 17 years of age with a history of GPP treated with subcutaneous SPEVIGO (Study Effisayil-2), and evidence from an adequate and well-controlled study of intravenous SPEVIGO in adults with GPP (Study Effisayil-1), with additional pharmacokinetic analyses showing similar drug exposure levels in adults and pediatric subjects 12 years of age and older and weighing 40 kg or more. The safety and effectiveness of SPEVIGO in pediatric patients younger than 12 years of age or in pediatric patients weighing less than 40 kg have not been established.

Please see SPEVIGO Prescribing Information, including Medication Guide.

About ANZUPGO® (delgocitinib) Cream

ANZUPGO® (delgocitinib) cream is currently FDA-approved in the U.S. as the first and only topical pan-JAK treatment for chronic hand eczema (CHE). Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended.41 ANZUPGO cream is also approved in the European Union, United Kingdom, Switzerland, United Arab Emirates and Canada under the brand name ANZUPGO for the treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets.

ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.41,42

In 2014, LEO Pharma obtained the exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where Shionogi & Co., Ltd. owns the rights.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR ANZUPGO® (DELGOCITINIB) CREAM

What is ANZUPGO?

ANZUPGO is a prescription medicine used on the skin (topical) to treat moderate-to-severe chronic hand eczema (CHE) in adults who are not well-controlled with or cannot use topical corticosteroids.

The use of ANZUPGO along with other JAK inhibitors or strong immunosuppressants is not recommended.

IMPORTANT SAFETY INFORMATION

ANZUPGO is for use on the skin (topical use) only. Do not use ANZUPGO in or on your eyes, mouth or vagina.

What is the most important information I should know about ANZUPGO?

ANZUPGO may cause serious side effects, including:

Serious Infections: ANZUPGO may increase your risk of infections. ANZUPGO contains delgocitinib. Delgocitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth or applying on the skin, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body.

Contacts

Samantha Cranko

U.S. & Canada Communications

Email: media@leo-pharma.com

Jes Broe Frederiksen

Global Communications

Email: jebfe@leo-pharma.com

Read full story here

REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD

ReproNovo SA

/ Key word(s): Personnel

REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD

20.03.2026 / 13:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


 REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD

Biopharma executive with more than 35 years of leadership across C-suite and board roles

Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors.

Mark Altmeyer brings more than 35 years of experience as a biopharma executive and board leader across large pharma and high-growth biotech companies focusing on multiple therapeutic areas. He has deep expertise in commercialization strategy, M&A and international expansion, with a strong track record of driving growth and enterprise value in both public and private company settings. Altmeyer is recognized for fostering high-performing teams, aligning investors and management around clear value-creation priorities.

“Mark is distinguished by a rare blend of board-level leadership and operational excellence covering the full biopharma lifecycle, combining entrepreneurial drive with disciplined governance and a strategic, stakeholder-oriented mindset,” said Jean Marie Duvall, Chief Executive Officer and Co-Founder of ReproNovo. “He has successfully guided companies through critical development and strategic inflection points, capabilities that will be highly valuable as we globally advance RPN-001 and RPN-002 across four indications in fertility and women’s health.”

Most recently, Altmeyer served as Founder and CEO of Arvelle Therapeutics, where he led the company’s transatlantic build-out, secured $200 million in financing and successfully completed a $1 billion acquisition by Angelini Pharma within two years. His earlier roles include CCO at Axovant, as well as senior commercial and general management positions at Bristol Myers Squibb and Otsuka. At Otsuka, he led the launch and expansion of Abilify to become the top selling pharmaceutical product in the U.S. in 2013, increasing revenue to over $7 billion. Across Altmeyer’s career, his leadership has spanned multiple therapeutic areas and business models, from primary care and specialty pharma to rare disease and hospital-driven markets.

In addition to his executive experience, Altmeyer adds extensive board-level leadership across the biotech lifecycle, from early-stage development through late-stage growth and exit. He currently serves as Chairman of AM-Pharma and Calluna Pharma and holds non-executive or independent director roles at several public and private life sciences companies. From 2016 to 2018, Altmeyer served as an Independent Director at Myovant Sciences, which was subsequently acquired by Sumitomo Pharma in a transaction valued at approximately $3 billion.

Commenting on his appointment, Mark Altmeyer said: “ReproNovo is addressing critical therapeutic gaps in areas that have seen limited innovation, despite these being really large markets. I look forward to working with the Board and management team to maximize these highly differentiated products, create value and ultimately bring these products to patients.”

ABOUT REPRONOVO:
ReproNovo is a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health. Our team is composed of proven experts with deep experience in reproductive medicine, drug development, regulatory affairs and business development who have throughout their careers successfully brought multiple therapies to market. ReproNovo’s lead clinical compound, RPN-001 (leflutrozole), is currently being evaluated in a U.S. Phase 2 trial in men with low sperm count and low testosterone (NCT06993155). RPN-002 (nolasiban) is in development to improve embryo implantation success rates and for the management of adenomyosis. ReproNovo is financed by Jeito Capital, BNP Paribas Asset Management Alts (formerly AXA IM Alts), founding investor M Ventures, Ysios Capital and ALSA Ventures. Headquartered in Lausanne, Switzerland, the company has its primary development team in Copenhagen, Denmark and an additional development site in Barcelona, Spain, with clinical and operational team members also based in the U.S. For more information, visit the Company’s website at www.repronovo.com or follow us on LinkedIn.

CONTACT INFORMATION:
ReproNovo
Rue de Langallerie 11
1003 Lausanne, Switzerland
info@repronovo.com

MEDIA CONTACT:
MC Services AG
Brittney Sojeva
repronovo@mc-services.eu
+49 211 529 252 14

Mark Altmeyer

Mark Altmeyer


20.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2294576  20.03.2026 CET/CEST

BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT




BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

Financing strengthens balance sheet and supports advancement of key development initiatives

NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) — Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million.

In connection with the financing, the Company issued an aggregate of approximately 21,071,667 shares of its common stock at a purchase price of approximately $0.055 per share. Investors also received warrants to purchase up to 19,750,001 additional shares of common stock at an exercise price of $0.12 per share. The warrants have a term of five years from the date of issuance.

The securities were offered and sold in a private placement pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

The Company intends to use the net proceeds from the financing for working capital and general corporate purposes, including advancing its development programs and supporting selected commercialization initiatives.

“This financing strengthens our balance sheet and supports the advancement of our clinical and development initiatives,” said David Platt, PhD, Chief Executive Officer of Bioxytran. “In parallel, we are beginning to translate our galectin-targeting platform into commercial opportunities, including the market introduction of A-SUQAR®, our plant-derived dietary supplement expected to launch this quarter. This dual-track approach allows us to pursue near-term commercialization while continuing to advance our higher-value pharmaceutical programs.”

The warrants issued in connection with the financing provide the potential for additional capital upon exercise, further supporting the Company’s long-term growth plans.

About Bioxytran, Inc.

Bioxytran, Inc. is a biotechnology company focused on the development of therapeutics targeting hypoxia-related conditions and galectin-targeting carbohydrate technologies, with applications across infectious viral diseases, metabolic health, and inflammation. The company leverages proprietary technologies to address significant unmet medical needs, with programs spanning pharmaceutical development and select commercial applications.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the use of proceeds, future development plans, anticipated commercialization activities, and potential warrant exercises. Actual results may differ materially from those projected due to various factors. Bioxytran undertakes no obligation to update these statements except as required by law.

For more information, please visit:
www.bioxytraninc.com

Investor Contact:
David Platt, PhD
CEO, Bioxytran, Inc.
617-484-1199
David.Platt@bioxytraninc.com

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET




RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company’s website at https://ir.renovorx.com/.

On the call, RenovoRx’s management team is expected to discuss the continued progress in RenovoCath adoption among U.S. cancer centers, strengthening clinical and commercial momentum.

Management will also provide an update on the advancement of RenovoRx’s clinical pipeline, including the Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer, which remains on track to complete enrollment in the first half of 2026, with final data expected in 2027. The Company will discuss its strategy for generating new data through post-marketing registry studies in solid tumors and continued support of investigator-initiated trials (IIT) in borderline resectable and metastatic pancreatic cancer, along with exploring physician interest in other areas. Registry and IIT trials achieve cost neutrality as capital-efficient studies providing meaningful data that may further broaden the application for the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.

Event: RenovoRx Fourth Quarter and Full Year 2025 Financial Results and Business
Highlights Conference Call
Date: Monday, March 30, 2026
Time: 4:30 p.m. ET
Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International)
Webcast: https://ir.renovorx.com/news-events/ir-calendar-events
 

For interested individuals unable to join the conference call, a link to the recording will be available on RenovoRx’s Investor Relations website, and a dial-in replay will be available until April 13, 2026 and can be accessed by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International) and entering replay pin number 13758677.

About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

RenovoRx is in the initial stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately $900,000 of revenues were generated from RenovoCath sales. Several customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements
This press release, the conference call described herein, and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate;(v) that the applicable regulatory authorities may disagree with our interpretation of the data, research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRX@KCSA.com

WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial

WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial




WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial

IRVINE, Calif., March 20, 2026 (GLOBE NEWSWIRE) — WallabyPhenox today announced the successful treatment of the first U.S. patient in the p48 and p64 MW HPC in Aneurysm Occlusion (PIANO) IDE trial, evaluating the p48 and p64 MW HPC Flow Modulation Devices for the treatment of intracranial aneurysms. The first two procedures were performed by Adel Malek, MD, PhD, Chief of Neurovascular Surgery at Tufts Medical Center in Boston, MA.

“Initiating the PIANO IDE trial is an important milestone in our company’s history and demonstrates our commitment to bringing life-saving innovations to patients in the United States,” said Ruilin Zhao, CEO of WallabyPhenox.

Flow diversion is an established therapy for intracranial aneurysms. However, limited device options remain available to U.S. physicians. The p48 and p64 MW HPC flow diverters are the market leader in Germany.

“The p48 and p64 MW HPC devices have been used in the treatment of more than 20,000 patients worldwide, with data from rigorous studies conducted outside the United States demonstrating consistently high aneurysm occlusion rates and low complication rates,” said Gary Brogan, VP of Global Clinical & Regulatory Affairs.

The p48 & p64 MW HPC devices bring multiple novel features including the first Movable Wire (MW) technology designed for stable and controlled positioning. The Hydrophilic Polymer Coating (HPC) is designed to reduce thrombogenicity of the implant. Smaller microcatheter delivery simplifies procedural access. Lastly, the Nitinol wires with platinum core provide full radiographic visibility.

“We are pleased to usher in this unique flow diverter that the U.S. physician community has been eagerly awaiting,” said Demetrius Lopes, MD, who serves as the National Principal Investigator along with Jared Knopman, MD, and Eytan Raz, MD, PhD.

“We always welcome the opportunity to offer new innovations and technologies to our patients through cutting-edge clinical trials,” said Dr. Malek. “A device that proves to be safe, effective and efficient will only enhance our ability to treat intracranial aneurysms and ensure the best-possible outcomes for our patients.”

Enrollment in the PIANO IDE trial is ongoing at leading U.S. centers.

The p48 and p64 MW HPC Flow Modulation Devices are investigational devices in the United States and are limited by federal law to investigational use.

CONTACT Travis May
Director of Upstream Marketing
EMAIL Travis.May@wallabyphenox.com 
COMPANY WallabyPhenox

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis




Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations

LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the clinical foundation for Nodify CDT® tests as a critical decision-support tool in the early detection of lung cancer, addressing a significant unmet need in the management of the millions of lung nodules detected annually in the United States. 

The study, published in Future Oncology, February 2026, titled Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30mm pulmonary nodules: a retrospective pooled analysis of four cohort studies, highlights that the Nodify CDT® test offers consistently strong performance in identifying a high risk of lung cancer in patients with lung nodules.

Over 1,100 patients with noncalcified lung nodules ranging in size from 4-30 mm and had Nodify CDT test results were analyzed. The data shows that the Nodify CDT test consistently demonstrated high specificity (91-97%), i.e., low false positive rates, regardless of nodule size or baseline patient risk factors. Test performance was also consistent across four distinct clinical studies with patients enrolled from 48 clinical practices in the US, including the CLARIFY study (NCT06728319) where patients received the Nodify CDT test as part of real-world clinical care. These data substantiate that the Nodify CDT test has strong clinical applicability and consistent performance across diverse practice settings.

“Most small nodules are benign and clinicians must balance patient care decisions … whether to ‘watch and wait’ with imaging surveillance or, instead, to expedite intervention based on the limited insights provided by the CT scan,”  said Dr. James Jett, Co-Chief Medical Officer at Biodesix, former Pulmonologist at Mayo Clinic, and Professor of Medicine Emeritus of National Jewish Health in Denver, CO.1 Dr. Jett emphasized, “A recent study reported in the journal THORAX (by The SUMMIT consortium) observed that over 40% of malignant pulmonary nodules progressed in tumor size between the time of first detection and the time of definitive treatment.2 This highlights a clinician’s need for more helpful decision-support tools to expedite diagnosis and treatment, such as Nodify Lung® Nodule Risk Assessment.”

“The data shows that the Nodify CDT test detected lung cancer with minimal false positives for nodules 4-30 mm in size,” confirmed Dr. Luke Yuhico, Pulmonologist, Fort Walton-Destin Hospital, FL.  “In my own practice, I have observed that using Nodify Lung testing, in conjunction with the information on the patient’s scan, significantly assists in my team’s decision-making as we strive to meaningfully impact patient outcomes by finding cancer much earlier, even in very small nodules.”

“This comprehensive validation study supports our continued commercial expansion of the Nodify CDT test and reinforces its clinical utility in addressing the substantial market opportunity and system-wide gaps in patient care that are presented by lung nodule management,” said Scott Hutton, CEO & President, Biodesix. “The demonstrated consistency of Nodify CDT tests, across real-world practice settings, further strengthens the company’s offering with healthcare providers, payers, and clinical guideline committees.”

The Nodify CDT test is available for clinical use in patients with 4-30 mm lung nodules. To learn more about Nodify Lung testing, or to order a test for a patient, please visit www.biodesix.com.

Footnotes:
1.  Dr. James Jett, Co-Chief Medical Officer at Biodesix, is a board-certified physician in pulmonary medicine and served at the Mayo Clinic in Rochester, MN for 28 years. His is also Professor of Medicine Emeritus of National Jewish Health in Denver, CO.  He served as the Editor-in-Chief of the Journal of Thoracic Oncology and as Co-Editor of the Lung Cancer Section of the premier medical electronic textbook Up-To-Date.
2.  Upstaging of screen-detected lung cancers during diagnostic assessment, published as 10.1136/thorax-2025-224006, 2 Feb 2026, http://thorax.bmj.com/. Monica L Mullin, Priyam Verghese, Chuen R Khaw, Andrew Creamer, Amyn Bhamani, Ruth Prendecki, Jennifer L Dickson, Carolyn Horst, Sophie Tisi, Helen Hall, Kylie Gyertson, Esther Arthur-Darkwa, Laura Farrelly, John McCabe, Ricky Thakrar, Arjun Nair, Anand Devaraj, Neal Navani, Allan Hackshaw, The SUMMIT consortium, Sam M Janes.

About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843